Shop by goal

Popular compounds

GHK-Cu

Retatrutide

Tirzepatide

Semaglutide

All bestsellers →

Research resources

Certificates of Analysis

Sweden, Melanoma & Melanotan-2: What the Research Actually Says

Q: Why does Sweden have such high melanoma rates?

The Swedish Melanoma Registry and Nordcan data show Sweden among the highest melanoma incidence countries in Europe. The literature attributes this to a combination of fair Fitzpatrick I-II phototype prevalence, intermittent intense UV exposure during summer holidays at lower latitudes, a long-standing sunbed culture (though now in decline), and effective dermatological surveillance that captures more cases.

Q: Does Melanotan-2 prevent melanoma?

No. There is no peer-reviewed evidence that Melanotan-2 prevents melanoma in humans. The published literature instead contains multiple case reports of nevus darkening, eruptive dysplastic nevi, and melanoma developing in MT-2 users (Cardones & Grichnik 2009; Langan et al. 2009; Paurobally et al. 2011; Hjuler & Lorentzen 2014). MT-2 is not approved for any therapeutic use anywhere in the world.

Q: What is the difference between Melanotan-2 and afamelanotide (Scenesse)?

Afamelanotide (marketed as Scenesse) is a more MC1R-selective linear analogue of alpha-MSH that received EMA approval in 2014 and FDA approval in 2019 for the very specific orphan indication of erythropoietic protoporphyria (EPP). Melanotan-2 is a non-selective MC1/3/4/5 receptor agonist that has never been approved for any therapeutic use and is sold worldwide only as a research compound.

Q: What does the dermatology literature actually recommend for primary melanoma prevention?

Established primary prevention measures with supporting trial evidence include broad-spectrum sunscreen use (Green et al., JCO 2011), avoidance of indoor tanning beds (Boniol et al., BMJ 2012; IARC Group 1 carcinogen), reducing intermittent intense UV exposure, and total-body skin examination at intervals appropriate to risk phenotype. None of this body of work supports pharmacological tanning as a prevention strategy.

Sweden is one of the most studied countries in the world for cutaneous melanoma. It also happens to be the kind of place where a synthetic melanocortin agonist like Melanotan-2 turns up in conversation more than the published evidence would justify - pale phototypes, dark winters, summer sun on the Mediterranean. This piece is the honest version of that conversation: what the Swedish epidemiology actually shows, what the dermatology literature says about primary prevention, and where MT-2 sits in the melanocortin receptor research landscape once you stop reading forum posts and start reading the journals.

One sentence up front. The claim that Melanotan-2 prevents melanoma is not supported by the published literature. The peer-reviewed record actually contains the opposite signal - multiple case reports of nevus darkening, eruptive dysplastic nevi, and melanoma developing during MT-2 self-administration. MT-2 is a research compound, not a clinical prevention tool, and this article does not recommend its use in humans for any purpose.

1. The Swedish Melanoma Picture, in Numbers

The Swedish Melanoma Registry (SweMR), running since 1990 and covering essentially the entire population, makes Sweden one of the best-documented melanoma cohorts in the world. The headline numbers are striking enough on their own:

Sweden sits in the top tier of European melanoma incidence, with age-standardised rates that the Nordcan database (Engholm et al., Acta Oncologica ) has tracked rising steadily for four decades.

Lyth and colleagues ( Acta Dermato-Venereologica , 2017) documented continued increases in both thin and thick melanomas through the 2000s - a pattern that mixed-mode early detection alone cannot explain.

The Swedish Cancer Society’s 2020s reporting puts cutaneous melanoma among the fastest-growing cancers in the country, with annual incidence increases historically averaging around 4–5% per year in adults.

Mortality has risen more slowly than incidence, consistent with both earlier detection and a real underlying rise in disease burden.

For comparison, Australia and New Zealand are the only consistently higher-incidence countries; Sweden, Norway and Denmark form a Nordic cluster that punches far above its latitude.

2. Why Sweden? The Four Drivers in the Literature

The published epidemiology converges on a roughly four-part explanation for the Nordic paradox - high melanoma rates despite low ambient UV at home.

Driver What it is Representative evidence Phototype High prevalence of Fitzpatrick I–II skin (fair, freckles, burns easily, tans poorly) - the phenotype with the strongest melanoma association. Bliss et al., Int J Cancer , 1995; Olsen et al. pooled analyses across Nordic cohorts. Intermittent intense UV The classic “sunburn on holiday” pattern - long pale winters, then concentrated UV exposure at lower latitudes, often with episodic burns. Elwood & Jopson meta-analysis, Int J Cancer , 1997; Gandini et al. systematic review, Eur J Cancer , 2005. Indoor tanning (sunbeds) Strong historical sunbed culture in Sweden and Norway, particularly among women under 30. Now declining following regulation, but cohort effects persist. Veierød et al., JNCI , 2003 (Norwegian/Swedish Women’s Lifestyle & Health cohort); Boniol et al., BMJ , 2012 (meta-analysis); IARC Group 1 carcinogen classification, 2009. Surveillance density High dermatology access and a complete national registry catch more thin lesions, lifting recorded incidence. Lyth et al., Acta Derm Venereol , 2017; Swedish Melanoma Registry annual reports.

Note what is not on that list: there is no published claim in this literature that Sweden’s melanoma rate is high because Swedes lack pigment-stimulating peptides. The pathway runs the other way - pale phototype is a marker of low MC1R signalling efficiency at the population level, but the established interventions all target the UV exposure side, not the pigment-pharmacology side.

3. What Primary Prevention Actually Looks Like in the Evidence

The dermatology community has converged on a fairly narrow set of primary-prevention interventions with supporting trial or cohort evidence:

Broad-spectrum sunscreen, used regularly. Green et al. ( Journal of Clinical Oncology , 2011) reported a roughly 50% reduction in invasive melanoma incidence at 10-year follow-up of the Nambour skin-cancer-prevention trial in regular daily sunscreen users versus discretionary use. That is one of the only randomised primary-prevention trials in the entire field, and its result is now baked into national guidance, including in Sweden.

Avoiding indoor tanning. The Boniol et al. BMJ meta-analysis (2012) put first-exposure-before-35 sunbed use at roughly a 59–75% increased melanoma risk, and tied a measurable share of European melanoma cases directly to sunbeds. This is the evidence base for the IARC Group 1 carcinogen classification and the Swedish Radiation Safety Authority’s sunbed regulations.

Reducing intermittent intense UV exposure. The pooled cohort evidence shows it is the burn pattern, not just total UV dose, that drives melanoma risk - supporting behavioural advice around midday sun, shade, and clothing.

Risk-tailored skin surveillance. For Fitzpatrick I–II individuals with personal or family melanoma history or atypical nevi, total-body photography and dermoscopic surveillance shorten time-to-diagnosis of thin lesions. The Swedish dermatology guidelines have built this in.

None of the major position statements - Swedish, European (EADO), or the EU Code Against Cancer 4th Edition - recommend any pharmacological tanning agent as a primary or secondary prevention strategy. The literature isn’t silent on the question; it has answered it.

4. Where Melanotan-2 Actually Sits in the Melanocortin Research Landscape

Melanotan-2 (MT-2) is a cyclic lactam-bridged heptapeptide analogue of α-MSH, originally synthesised at the University of Arizona by Victor Hruby’s group ( Journal of Medicinal Chemistry , 1995). It is a non-selective agonist at all four melanocortin receptors - MC1R (skin pigmentation), MC3R (energy balance), MC4R (appetite and sexual behaviour) and MC5R (exocrine secretion). The receptor pharmacology is well characterised. What is much less well established is anything you would call a clinical role.

The closest a melanocortin agonist has come to a regulated tanning-adjacent indication is afamelanotide - a more MC1R-selective linear α-MSH analogue marketed as Scenesse . Afamelanotide received EMA approval in 2014 and FDA approval in 2019 for a single orphan indication: erythropoietic protoporphyria (EPP), a rare metabolic photosensitivity disorder where eumelanin loading buys patients enough UV tolerance to leave the house. It is approved for EPP, full stop. It is not approved for cosmetic tanning, melanoma prevention, fair-skin protection, or anything else, in any jurisdiction.

Melanotan-2, by contrast, has never been approved for any therapeutic indication anywhere. It is a research compound. The European Medicines Agency, the UK MHRA, and equivalent bodies across Scandinavia have issued public warnings about unregulated MT-2 use stretching back to 2008.

The distinction that gets blurred. Afamelanotide (Scenesse) is a regulated medicine for a specific genetic disease. Melanotan-2 is a research peptide sold as a laboratory reagent. They are related molecules, but they are not interchangeable, and the existence of the first does not validate human use of the second.

5. What the MT-2 Case-Report Literature Actually Shows

This is the part of the conversation that the “perfect tanning tool” framing omits. The peer-reviewed safety record for unregulated Melanotan-2 self-administration is short, but the signal in it points in a consistent direction:

Cardones & Grichnik , Pigment Cell & Melanoma Research , 2009 - reported eruptive dysplastic nevi and a melanocytic lesion concerning for melanoma in a user of an “Internet tanning peptide” later identified as MT-2.

Langan et al. , BMJ , 2009 and British Journal of Dermatology , 2010 - described darkening of nevi, new dysplastic nevi, and clinical concerns following MT-2 self-injection in case series.

Paurobally et al. , Dermatology , 2011 - melanoma in situ developing in a young MT-2 user.

Hjuler & Lorentzen , Clinical and Experimental Dermatology , 2014 - a Scandinavian case series of striking nevus changes during MT-2 use, directly relevant to the Nordic population we’re discussing in this article.

Habbema et al. , International Journal of Dermatology , 2017 - a comprehensive review of the “risks of unregulated use of α-MSH analogues”, summarising the dermatological, cardiovascular and neurological adverse events reported across the literature.

Ellis et al. , JAMA Dermatology , 2018 - review of MT-2 adverse events including melanocytic changes and systemic effects.

None of these papers individually proves that MT-2 causes melanoma. Case reports never can; the design isn’t built for it. But the body of work makes one thing inescapable: MT-2 demonstrably does darken existing nevi, has been associated with new atypical pigmented lesions, and has been temporally linked to melanoma in dermatology-published case reports. Whatever the eventual mechanistic resolution, that is not the safety profile of a prevention agent.

There is also a practical problem that the literature flags repeatedly: MT-2 makes existing moles darker, which obscures the very dermoscopic and photographic surveillance that is doing the work in Swedish primary prevention. A clinician trying to assess change-over-time in pigmented lesions in someone using MT-2 is, in effect, looking through frosted glass.

6. So Why Does the “Swedish Girls Use MT-2” Narrative Persist?

Because the underlying observation that drives it is partly true. Sunbed culture among young Nordic women was historically very strong; the desire to tan in a low-UV country is a real cultural pattern that the epidemiology literature has documented for decades. MT-2 enters that conversation as a forum-circulated “shortcut.” What gets dropped along the way is the published record - both the absence of any approved use, and the case-report safety signal that runs the opposite direction from the marketing.

The honest reading of the Swedish data is the boring one: the same population characteristics that make Nordic women susceptible to melanoma in the first place - Fitzpatrick I–II phototype, the burn pattern, indoor-tanning exposure, atypical-nevus prevalence - are exactly the characteristics that make introducing a non-selective melanocortin agonist into the picture a worse idea, not a better one. The intervention that actually has trial evidence behind it is daily sunscreen, plus avoiding indoor tanning, plus regular skin checks.

7. What MT-2 Is Useful For, in Research

It would be a stretch to write a piece this critical of unregulated MT-2 use without acknowledging where the compound does have a legitimate place - in in vitro and preclinical melanocortin pharmacology. As a non-selective agonist with characterised PK and a long published binding profile, MT-2 is a benchmark tool for mapping MC1R/MC3R/MC4R/MC5R biology. It contributed to the medicinal-chemistry path that produced FDA-approved bremelanotide (PT-141) for HSDD. That is the actual research value of the molecule. None of that translates to a recommendation for human pigmentation use.

8. The Honest Takeaway

Sweden’s melanoma rate is high for well-documented reasons that are unrelated to pigment pharmacology.

The interventions with actual trial evidence are sunscreen, avoiding sunbeds, reducing intermittent UV burns, and risk-tailored skin surveillance.

Afamelanotide (Scenesse) is a regulated MC1R-selective medicine approved only for erythropoietic protoporphyria. It is not a cosmetic tanning agent.

Melanotan-2 is a non-selective melanocortin agonist with no approved human use anywhere. The peer-reviewed safety record contains repeated case reports of nevus changes and melanoma diagnoses in users.

The legitimate role of MT-2 is as a laboratory tool for melanocortin pharmacology research, not as a tanning intervention.

Frequently Asked Questions

Why does Sweden have such high melanoma rates?

A combination of high Fitzpatrick I–II phototype prevalence, intermittent intense UV exposure on holidays, a long-standing sunbed culture (now in decline), and dense national surveillance through the Swedish Melanoma Registry. The Nordic countries collectively sit near the top of European incidence despite low ambient UV at home.

Does Melanotan-2 prevent melanoma?

No. There is no peer-reviewed evidence that MT-2 prevents melanoma in humans. The published case-report literature, including Cardones & Grichnik 2009, Langan et al. 2009–2010, Paurobally et al. 2011, Hjuler & Lorentzen 2014 and Habbema et al. 2017, points the other way - nevus darkening, eruptive atypical nevi, and melanoma diagnoses in MT-2 users.

What is the difference between Melanotan-2 and afamelanotide (Scenesse)?

Afamelanotide is a more MC1R-selective linear α-MSH analogue, EMA-approved (2014) and FDA-approved (2019) for the rare metabolic disease erythropoietic protoporphyria. Melanotan-2 is a non-selective cyclic heptapeptide agonist at MC1R/MC3R/MC4R/MC5R that has never been approved for any human therapeutic indication, anywhere.

What does the dermatology literature actually recommend for primary prevention?

Daily broad-spectrum sunscreen (Green et al., JCO , 2011), avoiding indoor tanning beds (Boniol et al., BMJ , 2012; IARC Group 1), reducing intermittent intense UV burns, and risk-tailored total-body skin examination. The Swedish, EADO and EU Code Against Cancer recommendations are aligned on these points and do not include any pharmacological tanning agent.

Is Melanotan-2 legal in Sweden?

Like in most European jurisdictions, MT-2 is not authorised as a medicine in Sweden. The Swedish Medical Products Agency (Läkemedelsverket) has issued public warnings about unregulated MT-2 use, in line with EMA and MHRA positions. Material supplied as a research reagent is sold for laboratory use only, not for human application.

What is Melanotan-2 actually useful for?

In a research setting, MT-2 is a well-characterised non-selective melanocortin receptor agonist used to probe MC1R/3R/4R/5R pharmacology in vitro and in preclinical animal models. It was historically the medicinal-chemistry stepping stone to bremelanotide (PT-141), the FDA-approved MC4R-selective agonist for HSDD. That is the legitimate research lane.

Selected References

Lyth J et al. Stage-Specific Direct Healthcare Costs and Survival in Patients with Cutaneous Malignant Melanoma. Acta Dermato-Venereologica , 2017.

Engholm G et al. NORDCAN - a Nordic tool for cancer information, planning, quality control and research. Acta Oncologica , 2010.

Veierød MB et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. Journal of the National Cancer Institute , 2003.

Boniol M et al. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ , 2012;345:e4757.

Green AC et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. Journal of Clinical Oncology , 2011;29(3):257–263.

Gandini S et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European Journal of Cancer , 2005;41(1):45–60.

IARC Working Group. A review of human carcinogens - Part D: radiation. The Lancet Oncology , 2009;10(8):751–752 (sunbed Group 1 classification).

Hruby VJ et al. Cyclic lactam α-melanotropin analogues with bulky aromatic amino acids at position 7. Journal of Medicinal Chemistry , 1995;38(18):3454–3461.

Cardones AR, Grichnik JM. α-Melanocyte–stimulating hormone-induced eruptive nevi. Pigment Cell & Melanoma Research , 2009.

Langan EA et al. Change in moles linked to use of unlicensed “sun tan jab.” BMJ , 2009;338:b277.

Langan EA et al. Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’? British Journal of Dermatology , 2010;163(3):451–455.

Paurobally D et al. Melanoma in situ in a patient using Melanotan. Dermatology , 2011;222(3):204–206.

Hjuler KF, Lorentzen HF. Melanoma associated with the use of Melanotan-II. Clinical and Experimental Dermatology , 2014.

Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of α-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology , 2017;56(10):975–980.

Ellis SR et al. Trends in dermatology-related Internet content. JAMA Dermatology , 2018.

European Medicines Agency. Scenesse (afamelanotide) Summary of Product Characteristics, 2014 (EU marketing authorisation).

U.S. Food and Drug Administration. Approval of Scenesse (afamelanotide) for erythropoietic protoporphyria, 2019.

Buy Melanotan-2 from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

Sweden, Melanoma & Melanotan-2: What the Research Actually Says

1. The Swedish Melanoma Picture, in Numbers

2. Why Sweden? The Four Drivers in the Literature

3. What Primary Prevention Actually Looks Like in the Evidence

4. Where Melanotan-2 Actually Sits in the Melanocortin Research Landscape

5. What the MT-2 Case-Report Literature Actually Shows

6. So Why Does the “Swedish Girls Use MT-2” Narrative Persist?

7. What MT-2 Is Useful For, in Research

8. The Honest Takeaway

Frequently Asked Questions

Why does Sweden have such high melanoma rates?

Does Melanotan-2 prevent melanoma?

What is the difference between Melanotan-2 and afamelanotide (Scenesse)?

What does the dermatology literature actually recommend for primary prevention?

Is Melanotan-2 legal in Sweden?

What is Melanotan-2 actually useful for?

Selected References

Related Reading

From the Lab - Peptides on LinkedIn & Facebook

Melanotan-2, Lab-Verified, Research Use Only.

Buy Melanotan-2 from New-U Research Compounds

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide